一只犬疑似因马西替尼诱发肾病综合征和氮质血症。
Presumed masitinib-induced nephrotic syndrome and azotemia in a dog.
作者信息
Devine Lauren, Polzin David J
机构信息
North Carolina State Veterinary Hospital - Internal Medicine, 1060 William Moore Drive, Raleigh, North Carolina 27607, USA (Devine); University of Minnesota - Internal Medicine, St. Paul, Minnesota, 55108, USA (Polzin).
出版信息
Can Vet J. 2016 Jul;57(7):752-6.
Abstract
Masitinib mesylate is a tyrosine-kinase inhibitor approved for the treatment of nonresectable or recurrent, Grade 2 or 3 mast cell tumors in dogs. This report describes nephrotic syndrome and acute kidney injury attributed to masitinib and illustrates the need for regular monitoring of serum creatinine concentration, urinalysis, and urine protein:creatinine ratio during its use.
摘要
甲磺酸马西替尼是一种酪氨酸激酶抑制剂，已被批准用于治疗犬不可切除或复发性2级或3级肥大细胞瘤。本报告描述了由甲磺酸马西替尼引起的肾病综合征和急性肾损伤，并说明了在使用期间定期监测血清肌酐浓度、尿液分析以及尿蛋白：肌酐比值的必要性。
相似文献
1
Presumed masitinib-induced nephrotic syndrome and azotemia in a dog.一只犬疑似因马西替尼诱发肾病综合征和氮质血症。
Can Vet J. 2016 Jul;57(7):752-6.
2
Masitinib is safe and effective for the treatment of canine mast cell tumors.马西替尼治疗犬肥大细胞瘤安全有效。
J Vet Intern Med. 2008 Nov-Dec;22(6):1301-9. doi: 10.1111/j.1939-1676.2008.0190.x. Epub 2008 Sep 24.
3
"Masitinib" is safe and effective for the treatment of canine mast cell tumors.马西替尼对犬肥大细胞瘤的治疗安全有效。
J Vet Intern Med. 2010 Jan-Feb;24(1):6; author reply 7. doi: 10.1111/j.1939-1676.2009.0433.x.
4
Toceranib phosphate-associated nephrotic syndrome in a dog: a case report.犬用磷酸替罗替尼相关性肾病综合征：一例病例报告。
BMC Vet Res. 2021 Apr 7;17(1):146. doi: 10.1186/s12917-021-02850-9.
5
Microalbuminuria is not associated with cisplatin-induced azotemia in dogs.微量白蛋白尿与犬顺铂诱导的氮质血症无关。
J Vet Intern Med. 2007 Nov-Dec;21(6):1198-202. doi: 10.1892/07-012.1.
6
A retrospective review of treatment and response of high-risk mast cell tumours in dogs.回顾性分析犬高危肥大细胞瘤的治疗及反应。
Vet Comp Oncol. 2016 Dec;14(4):361-370. doi: 10.1111/vco.12116. Epub 2014 Sep 15.
7
Masitinib mesylate for metastatic and non-resectable canine cutaneous mast cell tumours.甲磺酸马西替尼用于治疗转移性和不可切除的犬皮肤肥大细胞瘤。
Vet Comp Oncol. 2015 Sep;13(3):314-21. doi: 10.1111/vco.12053. Epub 2013 Jul 12.
8
Clinical response of masitinib mesylate in the treatment of canine macroscopic mast cell tumours.甲磺酸马西替尼治疗犬肉眼可见肥大细胞瘤的临床反应
J Small Anim Pract. 2016 Jun;57(6):283-90. doi: 10.1111/jsap.12480. Epub 2016 May 2.
9
Masitinib-associated minimal change disease with acute tubular necrosis resulting in acute kidney injury in a dog.犬体内出现与马西替尼相关的微小病变性肾病合并急性肾小管坏死，导致急性肾损伤。
J Vet Intern Med. 2013 Nov-Dec;27(6):1622-6. doi: 10.1111/jvim.12189. Epub 2013 Sep 10.
10
Comparison of signalment, clinicopathologic findings, histologic diagnosis, and prognosis in dogs with glomerular disease with or without nephrotic syndrome.比较有或无肾病综合征的肾小球疾病犬的一般情况、临床病理发现、组织学诊断和预后。
J Vet Intern Med. 2011 Mar-Apr;25(2):206-14. doi: 10.1111/j.1939-1676.2010.0669.x. Epub 2011 Jan 31.
引用本文的文献
1
A Scoping Review on Tyrosine Kinase Inhibitors in Cats: Current Evidence and Future Directions.猫酪氨酸激酶抑制剂的范围综述：当前证据与未来方向
Animals (Basel). 2023 Sep 29;13(19):3059. doi: 10.3390/ani13193059.
2
Toceranib phosphate-associated nephrotic syndrome in a dog: a case report.犬用磷酸替罗替尼相关性肾病综合征：一例病例报告。
BMC Vet Res. 2021 Apr 7;17(1):146. doi: 10.1186/s12917-021-02850-9.
3
A retrospective study of proteinuria in dogs receiving toceranib phosphate.一项关于接受磷酸托西拉尼的犬蛋白尿的回顾性研究。
Can Vet J. 2018 Jun;59(6):611-616.
本文引用的文献
1
Masitinib-associated minimal change disease with acute tubular necrosis resulting in acute kidney injury in a dog.犬体内出现与马西替尼相关的微小病变性肾病合并急性肾小管坏死，导致急性肾损伤。
J Vet Intern Med. 2013 Nov-Dec;27(6):1622-6. doi: 10.1111/jvim.12189. Epub 2013 Sep 10.
2
Masitinib mesylate for metastatic and non-resectable canine cutaneous mast cell tumours.甲磺酸马西替尼用于治疗转移性和不可切除的犬皮肤肥大细胞瘤。
Vet Comp Oncol. 2015 Sep;13(3):314-21. doi: 10.1111/vco.12053. Epub 2013 Jul 12.
3
Occurrence of infection among children with nephrotic syndrome during hospitalizations.肾病综合征患儿住院期间感染的发生情况。
Nephrology (Carlton). 2012 Nov;17(8):681-8. doi: 10.1111/j.1440-1797.2012.01650.x.
4
Interventions for preventing infection in nephrotic syndrome.预防肾病综合征感染的干预措施。
Cochrane Database Syst Rev. 2012 Apr 18;2012(4):CD003964. doi: 10.1002/14651858.CD003964.pub3.
5
Nephrotic syndrome in dogs: clinical features and evidence-based treatment considerations.犬肾病综合征：临床特征与循证治疗考量
Top Companion Anim Med. 2011 Aug;26(3):135-42. doi: 10.1053/j.tcam.2011.04.004.
6
Biological effect of tyrosine kinase inhibitors on three canine mast cell tumor cell lines with various KIT statuses.酪氨酸激酶抑制剂对三种具有不同KIT状态的犬肥大细胞瘤细胞系的生物学效应。
J Vet Pharmacol Ther. 2012 Feb;35(1):97-104. doi: 10.1111/j.1365-2885.2011.01296.x. Epub 2011 Apr 12.
7
Masitinib as a chemosensitizer of canine tumor cell lines: a proof of concept study.马替尼作为犬肿瘤细胞系化疗增敏剂的研究：概念验证研究。
Vet J. 2012 Jan;191(1):131-4. doi: 10.1016/j.tvjl.2011.01.001. Epub 2011 Feb 17.
8
Safety of masitinib mesylate in healthy cats.甲磺酸马替尼在健康猫中的安全性。
J Vet Intern Med. 2011 Mar-Apr;25(2):297-302. doi: 10.1111/j.1939-1676.2011.0687.x. Epub 2011 Feb 11.
9
Comparison of signalment, clinicopathologic findings, histologic diagnosis, and prognosis in dogs with glomerular disease with or without nephrotic syndrome.比较有或无肾病综合征的肾小球疾病犬的一般情况、临床病理发现、组织学诊断和预后。
J Vet Intern Med. 2011 Mar-Apr;25(2):206-14. doi: 10.1111/j.1939-1676.2010.0669.x. Epub 2011 Jan 31.
10
Clinical trial on the efficacy of masitinib in canine IBD.马西替尼治疗犬类炎症性肠病疗效的临床试验。
Vet Rec. 2010 Nov 6;167(19):760. doi: 10.1136/vr.c6030.
Zotero 插件